Asia Pacific to Witness Tremendous Growth in the Breast Cancer Detection Market

According to Custom Market Insights (CMI), the Global Breast Cancer Detection Market size was estimated at USD 5 Billion in 2021 and is expected to hit around USD 7.5 Billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 6% from 2022 to 2030.

Our research report offers a 360-degree view of the Breast Cancer detection market’s drivers and restraints, coupled with the impact they have on demand during the projection period. Also, the report examines global opportunities and competitive analysis for the Breast Cancer Detection market.

Breast Cancer Detection Market: Overview

One of the most prevalent cancers in the world and a major factor in the death of women is breast cancer. So, in order to treat breast cancer disorders, early detection is necessary. Due to their modern lifestyles, industrialized nations have a higher prevalence of breast cancer, while undeveloped nations have a higher incidence rate. According to the World Health Organization, 2.3 million women worldwide had a breast cancer diagnosis in 2020, and there were 685,000 breast cancer-related deaths.

Browse the full “Breast Cancer Diagnostics Market Size, Trends, and Insights By Type (Imaging, Genomic Tests, Biopsy, Blood Tests, Others), By Product (Platform-based Products, Next-generation Sequencing, PCR, Microarrays, Others, Instrument-based Products, Biopsy, Imaging), By Application (Screening, Prognostic, Diagnostic and Predictive, Research), By End-use (Diagnostic Centers and Medical Laboratories, Hospitals & Clinics, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032 “ report at https://www.custommarketinsights.com/report/breast-cancer-diagnostics-market/

Growth Factors

The growth of global breast cancer detection is largely due to the aging population’s increased exposure to breast cancer risk, early detection, and growing public awareness of breast cancer.

The market expansion is aided by the advent of 3D mammography, also referred to as digital breast tomosynthesis, which is more accurate than 2D mammography. Compared to 2D mammography, this cutting-edge technology can detect 40.0% more tumors while requiring fewer patient recalls. In the anticipated period, the market is predicted to be driven in large part by the quick advancement of technology.

The expansion of the breast cancer Detection market is responsible for the rising number of breast cancer cases in women around the world. Additionally, the market is expanding as a result of rising government initiatives, advantageous reimbursement policies, and growing technological use. Additionally, increasing public awareness has a favorable effect on the market.

Segmental Overview

The market for Breast Cancer Detection is segmented into type, product, application, and end-use. In 2021, the imaging category, which accounted for the biggest revenue share of around 70%, dominated the market for breast cancer Detection. The market is expected to be driven by factors including the high number of procedures, ease of accessibility, and improved efficacy. Mammography, ultrasound, and MRI are the three imaging techniques used most frequently for screening and diagnosis. In addition, the development of a number of cutting-edge imaging methods for the diagnosis of breast cancer, including breast tomosynthesis, molecular breast imaging (MBI), CT, and PET, are anticipated to transform the field of breast imaging.

The market for breast cancer Detection was dominated by the hospitals and clinics sector in 2021, which also had the biggest revenue share of about 50.2%. The segment’s growth is anticipated to be fueled by rising patient hospitalization rates and the burden of disease. Patients receive a biopsy for confirmation testing in hospitals following the screening test. Additionally, PET, CT, and MRI are employed to monitor disease development and evaluate the efficacy of cancer treatment.

Regional Overview

Due to the rising incidence of breast cancer as well as the adoption of cutting-edge diagnostic methods, the market for breast cancer Detection in the Asia Pacific is anticipated to experience the greatest CAGR over the forecast period. Additionally, it is anticipated that expanding healthcare infrastructure and bettering reimbursement policies will promote market growth.

Report Scope

Feature of the Report Details
Market Size in 2021 USD 5 Billion
Projected Market Size in 2030 USD 7.5 Billion
Market Size in 2022 USD 5.2 Billion
CAGR Growth Rate 6% CAGR (2022-2030)
Base Year 2022
Forecast Period 2023-2032
Prominent Players Hologic Inc., Thermo Fisher Scientific Inc., BD, Genomic Health (Exact Sciences Corporation), Danaher, Koninklijke Philips N.V., QIAGEN, Myriad Genetics, F. Hoffmann-La Roche Ltd., Argon Medical Devices Inc., and Others
Key Segment By Type, Product, Application, End-use, and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Competitive Landscape

Companies are using strategies that let them use their resources to improve their supply chain and support the creation of new products.

  • 2019: The acquisition of Genomic Health by Exact Sciences Corporation was made public, and it was anticipated that adding Genomic Health’s product line would strengthen the company’s market position and offerings.

Prominent Players

  • Hologic Inc.
  • Thermo Fisher Scientific Inc.
  • BD
  • Genomic Health (Exact Sciences Corporation)
  • Danaher
  • Koninklijke Philips N.V.
  • QIAGEN
  • Myriad Genetics
  • Hoffmann-La Roche Ltd.
  • Argon Medical Devices Inc.

The global Breast Cancer Detection market is segmented as follows:

By Type

  • Imaging
  • Genomic Tests
  • Biopsy
  • Blood Tests
  • Others

By Product

  • Platform-based Products
    • Next-generation Sequencing
    • PCR
    • Microarrays
    • Others
  • Instrument-based Products
    • Biopsy
    • Imaging

By Application

  • Screening
  • Prognostic
  • Diagnostic and Predictive
  • Research

By End-use

  • Diagnostic Centers and Medical Laboratories
  • Hospitals & Clinics
  • Others

By Region

North America

  • The U.S.
  • Canada
  • Mexico

Europe

  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America